A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using interferon-beta la (Rebif ®) as an open-label rater-blind calibrator (TOWER)

Chercheur principal: 

Jean-Pierre Bouchard

Organisme subventionnaire: 

Sanofi-Aventis (Canada)

Statut: 
Projet en cours

CIUSSS-CN Université Laval Alliance santé Québec